Latest progress
Salubris announced recently that its
recombinant human Neuregulin 1-anti-HER3 antibody fusion protein injection
(Domestic project code: SAL007) has been approved by NMPA for phase 1 trial for
HFpEF (heart failure with preserved ejection fraction).
Salubris’ first China-US dual registration
innovative biologics, SAL007 (US project code: JK07) is an NRG-1(neuregulin-1)
fusion antibody independently developed by Salubris Bio, a subsidiary of
Salubris, with global intellectual property, of which the target indications
are HFrEF (heart failure with reduced ejection fraction) and HFpEF (heart
failure with preserved ejection fraction).
At present, the phase 1 trial of SAL007 for
HFrEF is undergoing in both China and US, and the phase 1 trial for HFpEF has
been approved in both China and US.
In the future, Salubris will continue to
focus on the field of chronic diseases, meet the unmet clinical needs, develop
more valuable drugs, and improve the quality of patient’s life.
